Oncology update: what do all those acronyms mean?

por Hughes-Davies, L
Publicado 2006

Tamoxifen: the drug that came in from the cold

por Hughes-Davies, L, Caldas, C, Wishart, G C
Publicado 2009

Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial

por Pinder, S E, Campbell, A F, Bartlett, J M S, Marshall, A, Allen, D, Falzon, M, Dunn, J A, Makris, A, Hughes-Davies, L, Stein, R C
Publicado 2017

Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer

por Conefrey, C., Donovan, J.L., Stein, R.C., Paramasivan, S., Marshall, A., Bartlett, J., Cameron, D., Campbell, A., Dunn, J., Earl, H., Hall, P., Harmer, V., Hughes-Davies, L., Macpherson, I., Makris, A., Morgan, A., Pinder, S., Poole, C., Rea, D., Rooshenas, L.
Publicado 2020

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

por Earl, H.M., Hiller, L., Dunn, J., Macpherson, I., Rea, D., Hughes-Davies, L., McAdam, K., Hall, P., Mansi, J., Wheatley, D., Abraham, J.E., Caldas, C., Gasson, S., O'Riordan, E., Wilcox, M., Miles, D., Cameron, D.A., Wardley, A.
Publicado 2021

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negativ...

por Earl, H. M., Hiller, L., Dunn, J. A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J. E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L.
Publicado 2017